Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | AHR | P35869 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1250296 | 0.90 | DGAT1 (0.67) | DGAT1HDAC6MEN1KMT2ACYP3A4 | |
| SCHEMBL1249943 | 0.87 | DGAT1 (0.69) | DGAT1HDAC6NPC1RAB9AMEN1 | |
| SCHEMBL26755194 | 0.85 | NPSR1 (0.66) | HDAC6NPC1RAB9ANPSR1TP53 | |
| SCHEMBL1248740 | 0.85 | DGAT1 (0.73) | DGAT1HDAC6NPC1RAB9AMEN1 | |
| SCHEMBL1251001 | 0.85 | DGAT1 (0.73) | DGAT1HDAC6NPC1RAB9ATP53 | |
| SCHEMBL1251146 | 0.85 | DGAT1 (0.72) | DGAT1HDAC6NPC1RAB9AMEN1 | |
| SCHEMBL1250958 | 0.85 | DGAT1 (0.69) | DGAT1HDAC6NPC1RAB9ANPSR1 | |
| SCHEMBL1250144 | 0.85 | DGAT1 (0.69) | DGAT1HDAC6NPC1RAB9AMEN1 | |
| SCHEMBL15252625 | 0.84 | DGAT1 (0.53) | DGAT1HDAC6NPC1RAB9AMEN1 | |
| SCHEMBL1248809 | 0.84 | DGAT1 (0.71) | DGAT1HDAC6NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046133-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885HDAC6 1155/4885NPC1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.